Review



t6128  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    TargetMol t6128
    T6128, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pha665752/PHA665752/pmc12718461-52-4-2
    Average 94 stars, based on 6 article reviews
    t6128 - by Bioz Stars, 2026-11
    94/100 stars

    Images

    Related Articles

    other:

    Article Title: HHLA2 activates c-Met and identifies patients for targeted therapy in hepatocellular carcinoma
    Article Snippet: 4 Antibodies and Drugs Suppliers Catalog Number Clonality Host Species Concentrations/ dilutions HHLA2/B7-H7 CST 52200S Monoclonal Rabbit WB 1:1000 HHLA2 Abcam ab214327 Polyclona l Rabbit IHC 1:100 c-Met Protein tech 25869-1-AP Polyclona l Rabbit WB 1:1000 IHC 1:500 p-Met(Tyr1234/1235) CST 3077S Monoclonal Rabbit WB 1:1000 IHC 1:100 HA-Tag CST 3724S Monoclonal Rabbit WB 1:1000 IHC 1:800 GAPDH Protein tech HRP-60004 Monoclonal Mouse WB 1:10000 VEGFA Protein tech 19003-1-AP Polyclona l Rabbit WB 1:2000 p44/42 MAPK (Erk1/2) CST 4695S Monoclonal Rabbit WB 1:1000 p-p44/42 MAPK(Erk1/2) CST 4370S Monoclonal Rabbit WB 1:2000 MMP9 (N-Termina l) Protein tech 10375-2-AP Polyclona l Rabbit WB 1:500 ICAM-1 Protein tech 10831-1-AP Polyclona l Rabbit WB 1:5000 HGF β CST 52445t Monoclonal Rabbit WB 1:1000 human N-cadher in Protein tech 22018-1-AP Polyclona l Rabbit WB 1:2000 E-cadher in Protein tech 60335-1-Ig Monoclonal Mouse WB 1:2000 Myc CST 2276S Monoclonal Mouse IHC 1:500 CD34 ABclonal A19015 Monoclonal Rabbit IHC 1:100 PHA665752 Targetmol T6128 In vitro 1μM In vivo 20 mg/kg Organoid 15μM Cabozant inib Yeasen 52724ES08 10μM Tunicamycin Beyotime SC0393-10mM 1 μg/ml Apat inib Beyotime SF5454-10mM 1 μM 5 Page | 2

    Article Title: Protocol for high-content drug screening using tumor organoids on a 384-pillar plate platform
    Article Snippet: PHA-665752 , Targetmol , T6128.

    Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer
    Article Snippet: Primary antibodies are used as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F-10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti-phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05–104, Sigma-Aldrich), anti-8-OHdG (sc-66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); PHA-665,752 (S1070; TargetMol), Dasatinib (CDS023389; Sigma-Aldrich), ML-385 (S8790; Selleckchem), Paclitaxel (T7191; Sigma-Aldrich);


    Fractionation:

    Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer.
    Article Snippet: .. Primary antibodies used are as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti- AR TIC LE IN PR ES S phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05-104, Sigma-Aldrich), anti-8-OHdG (sc66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); PHA-665752 (S1070; TargetMol), Dasatinib (CDS023389; Sigma-Aldrich), ML-385 (S8790; Selleckchem), Paclitaxel (T7191; Sigma-Aldrich); Protein extract, nuclei/cytoplasm fractionation and western blot analyses Total protein lysates were prepared using Buffer A (10 mM Hepes [pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.1% NP-40) or RIPA Buffer (50mM Tris-HCL pH 8.0, 150mM NaCl, 1% NP40, 12mM sodium deoxycholate) supplemented with 10 mg/ml Protease Inhibitor Cocktail-1 (P2714; Sigma-Aldrich), 10 mg/mL TPCK, 1mM phenylmethylsulfonyl fluoride, 25mM NaF, 1mM sodium orthovanadate, 25 mM β-glycerophosphate. ..

    Western Blot:

    Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer.
    Article Snippet: .. Primary antibodies used are as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti- AR TIC LE IN PR ES S phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05-104, Sigma-Aldrich), anti-8-OHdG (sc66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); PHA-665752 (S1070; TargetMol), Dasatinib (CDS023389; Sigma-Aldrich), ML-385 (S8790; Selleckchem), Paclitaxel (T7191; Sigma-Aldrich); Protein extract, nuclei/cytoplasm fractionation and western blot analyses Total protein lysates were prepared using Buffer A (10 mM Hepes [pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.1% NP-40) or RIPA Buffer (50mM Tris-HCL pH 8.0, 150mM NaCl, 1% NP40, 12mM sodium deoxycholate) supplemented with 10 mg/ml Protease Inhibitor Cocktail-1 (P2714; Sigma-Aldrich), 10 mg/mL TPCK, 1mM phenylmethylsulfonyl fluoride, 25mM NaF, 1mM sodium orthovanadate, 25 mM β-glycerophosphate. ..

    Protease Inhibitor:

    Article Title: Targeting of a novel interplay between MET tyrosine kinase and NRF2 enhances sensitivity to Paclitaxel in triple negative breast cancer.
    Article Snippet: .. Primary antibodies used are as follows: anti-NRF2 (D1Z9C) (12721; Cell Signalling Technology), anti-NRF2 (EP1808Y) (ab-62352; Abcam), anti-phospho-SRC (Tyr416) (2101; Cell Signalling Technology), anti-SRC (2108; Cell Signalling Technology), anti-phospho-MET (Tyr1234/35) (3126; Cell Signalling Technology), anti-MET (3127; Cell Signalling Technology), anti-heme oxygenase 1 (A-3) (sc-136960; Santa Cruz Biotechnology), anti-phospho-histone H2AX (Ser139) (9718; Cell Signalling Technology), anti-KEAP1 (G-2) (sc-365626; Santa Cruz Biotechnology), anti-KEAP1 (F10) (sc-514914; Santa Cruz Biotechnology), anti-p62 (SQSTM1) (PM045; MBL International), anti- AR TIC LE IN PR ES S phospho-p62 (SQSTM1) (Ser349) (PM074; MBL International), anti-phospho-EGFR (Tyr1068) (3777; Cell Signalling Technology), anti-EGFR (LA22) (05-104, Sigma-Aldrich), anti-8-OHdG (sc66036, Santa Cruz Biotechnology), anti-vinculin (13901; Cell Signalling Technology), anti-lamin A/C (sc-376248; Santa Cruz Biotechnology), anti-GAPDH (sc-47724; Santa Cruz Biotechnology), anti-β-Actin (3700, Cell Signalling Technology); PHA-665752 (S1070; TargetMol), Dasatinib (CDS023389; Sigma-Aldrich), ML-385 (S8790; Selleckchem), Paclitaxel (T7191; Sigma-Aldrich); Protein extract, nuclei/cytoplasm fractionation and western blot analyses Total protein lysates were prepared using Buffer A (10 mM Hepes [pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT, 0.1% NP-40) or RIPA Buffer (50mM Tris-HCL pH 8.0, 150mM NaCl, 1% NP40, 12mM sodium deoxycholate) supplemented with 10 mg/ml Protease Inhibitor Cocktail-1 (P2714; Sigma-Aldrich), 10 mg/mL TPCK, 1mM phenylmethylsulfonyl fluoride, 25mM NaF, 1mM sodium orthovanadate, 25 mM β-glycerophosphate. ..



    Similar Products

    94
    MedChemExpress c met inhibitor pha665752
    C Met Inhibitor Pha665752, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pha665752/PHA-665752/pm41845461-121-29-34
    Average 94 stars, based on 1 article reviews
    c met inhibitor pha665752 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol pha665752 targetmol t6128 in vitro
    Pha665752 Targetmol T6128 In Vitro, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pha665752/PHA-665752/pmc12090556__13046_2025_3407_MOESM1_ESM-1-152-153
    Average 94 stars, based on 1 article reviews
    pha665752 targetmol t6128 in vitro - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol t6128
    T6128, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pha665752/PHA665752/pmc12718461-52-4-2
    Average 94 stars, based on 1 article reviews
    t6128 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    Selleck Chemicals pha665752
    Fig. 2. Stimulation of STAT3-BCL2 axis by AURKB. (A) Gene set enrichment (GSEA) data of upregulated STAT3 target genes in the H1993 PR-S2 cells. (B) Protein expressions of p-STAT3, STAT3, and GAPDH. (C) Protein expressions of p-STAT3, STAT3, p-AURKB, AURKB, and GAPDH after barasertib single or <t>PHA665752</t> combination treatment of indicated drug concentration for 48 h. (D) Immunoblot analysis of the H1993 and H1993 PR-S2 cells transfected with scramble and siAURKB for 48 h. (E) and (F) The indicated protein ex pressions of the GFP and AURKB-GFP virus-infected H1993 stable cell lines and MG132 treatment for the indicated treatment time. The line graph represents the protein stability of p-STAT3. (G) and (H) RT-qPCR and immunoblotting measured the expressions of STAT3 downstream targets. (I) mRNA expression of BCL2 after treatment of 10, 100, and 1000 nM concentrations of barasertib. (J) mRNA expression levels of BCL2 and STAT3 in the scramble or siSTAT3 transfected H1993 and H1993 PR-S2 cells. (K) Protein expression of cleaved-caspase3 and BCL2 after treatment with barasertib for 48 h. The error bars represent the mean ± SEM (n = 3). Statistical analysis was performed using a two-sample t-test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001.
    Pha665752, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pha665752/PHA-665752/pm40499687-71-0-11
    Average 93 stars, based on 1 article reviews
    pha665752 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    TargetMol pha665752
    Fig. 2. Stimulation of STAT3-BCL2 axis by AURKB. (A) Gene set enrichment (GSEA) data of upregulated STAT3 target genes in the H1993 PR-S2 cells. (B) Protein expressions of p-STAT3, STAT3, and GAPDH. (C) Protein expressions of p-STAT3, STAT3, p-AURKB, AURKB, and GAPDH after barasertib single or <t>PHA665752</t> combination treatment of indicated drug concentration for 48 h. (D) Immunoblot analysis of the H1993 and H1993 PR-S2 cells transfected with scramble and siAURKB for 48 h. (E) and (F) The indicated protein ex pressions of the GFP and AURKB-GFP virus-infected H1993 stable cell lines and MG132 treatment for the indicated treatment time. The line graph represents the protein stability of p-STAT3. (G) and (H) RT-qPCR and immunoblotting measured the expressions of STAT3 downstream targets. (I) mRNA expression of BCL2 after treatment of 10, 100, and 1000 nM concentrations of barasertib. (J) mRNA expression levels of BCL2 and STAT3 in the scramble or siSTAT3 transfected H1993 and H1993 PR-S2 cells. (K) Protein expression of cleaved-caspase3 and BCL2 after treatment with barasertib for 48 h. The error bars represent the mean ± SEM (n = 3). Statistical analysis was performed using a two-sample t-test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001.
    Pha665752, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pha665752/PHA665752/pm40369167-52-0-10
    Average 94 stars, based on 1 article reviews
    pha665752 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology pha665752
    A) 0082T CAF cells were cultured in 21% or 1% O 2 for 72 hr, and qRT-PCR was performed for the indicated transcripts and normalized to CASC3 . n=3, t-test. B) 0082T CAFs were cultured in 21% or 1% O 2 for 120 hr, and immunofluorescence microscopy was performed for IGF-2. n=3, t-test. C) 430 inhibitors were screened for their ability to counteract hypoxic CAF-induced EMT in HPAF-II cells. HPAF-II cells were treated with hypoxic 0082T CM and inhibitors (1 μM for all compounds) for 120 hr. The ability of each inhibitor to reduce vimentin expression was calculated using positive and negative controls contained on each plate (see Methods). Data are displayed as a plot of the kernel density function (displayed as density) for the percent vimentin inhibition. Inhibitors with >50% reduction in vimentin-positive cells were designated as effective (orange region of the density plot of the inhibitor screen). D) Fraction of vimentin-positive HPAF-II cells treated with CM and MET inhibitors (blue) or MEK inhibitors (orange) compared to untreated and CM-only controls. The percentage of effective inhibitors was calculated for each inhibitor class in the inhibitor library. Representative images are shown of effective (i.e., >50% vimentin reduction) MEKi- or METi-treated samples and controls. E) 0082T cells were cultured in 21% or 1% O 2 for 120 hr and assessed for HGF expression by immunofluorescence microscopy. n=3, t-test. F) Immunofluorescence microscopy was performed on HPAF-II cells treated with hypoxic 0082T CM with linsitinib (IGF1Ri, 2.5 μM), <t>PHA665752</t> (METi, 2.5 μM), both, or DMSO. G) Immunofluorescence microscopy was performed on KPCY tumor samples to determine fraction of HGF-positive CAFs (PDPN+) in oxygenated (HYP-) or hypoxic (HYP+) tumor regions. n=3, paired t-test. Data are presented as mean ± SEM for bar plots (A, B, E, F) or as a box-and- whisker plot that represent the first quartile (lower box bound), median (center bound), or third quartile (upper box bound) (G). * p <0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Pha665752, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pha665752/PHA+665752/bio_rxiv__2025__01__30__635486-258-0-1
    Average 93 stars, based on 1 article reviews
    pha665752 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    95
    MedChemExpress pha665752 hy11107 afatinib
    A) 0082T CAF cells were cultured in 21% or 1% O 2 for 72 hr, and qRT-PCR was performed for the indicated transcripts and normalized to CASC3 . n=3, t-test. B) 0082T CAFs were cultured in 21% or 1% O 2 for 120 hr, and immunofluorescence microscopy was performed for IGF-2. n=3, t-test. C) 430 inhibitors were screened for their ability to counteract hypoxic CAF-induced EMT in HPAF-II cells. HPAF-II cells were treated with hypoxic 0082T CM and inhibitors (1 μM for all compounds) for 120 hr. The ability of each inhibitor to reduce vimentin expression was calculated using positive and negative controls contained on each plate (see Methods). Data are displayed as a plot of the kernel density function (displayed as density) for the percent vimentin inhibition. Inhibitors with >50% reduction in vimentin-positive cells were designated as effective (orange region of the density plot of the inhibitor screen). D) Fraction of vimentin-positive HPAF-II cells treated with CM and MET inhibitors (blue) or MEK inhibitors (orange) compared to untreated and CM-only controls. The percentage of effective inhibitors was calculated for each inhibitor class in the inhibitor library. Representative images are shown of effective (i.e., >50% vimentin reduction) MEKi- or METi-treated samples and controls. E) 0082T cells were cultured in 21% or 1% O 2 for 120 hr and assessed for HGF expression by immunofluorescence microscopy. n=3, t-test. F) Immunofluorescence microscopy was performed on HPAF-II cells treated with hypoxic 0082T CM with linsitinib (IGF1Ri, 2.5 μM), <t>PHA665752</t> (METi, 2.5 μM), both, or DMSO. G) Immunofluorescence microscopy was performed on KPCY tumor samples to determine fraction of HGF-positive CAFs (PDPN+) in oxygenated (HYP-) or hypoxic (HYP+) tumor regions. n=3, paired t-test. Data are presented as mean ± SEM for bar plots (A, B, E, F) or as a box-and- whisker plot that represent the first quartile (lower box bound), median (center bound), or third quartile (upper box bound) (G). * p <0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Pha665752 Hy11107 Afatinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pha665752/Afatinib/pm39567998-60-14-22
    Average 95 stars, based on 1 article reviews
    pha665752 hy11107 afatinib - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    MedChemExpress pha665752 hy 11107 afatinib
    A) 0082T CAF cells were cultured in 21% or 1% O 2 for 72 hr, and qRT-PCR was performed for the indicated transcripts and normalized to CASC3 . n=3, t-test. B) 0082T CAFs were cultured in 21% or 1% O 2 for 120 hr, and immunofluorescence microscopy was performed for IGF-2. n=3, t-test. C) 430 inhibitors were screened for their ability to counteract hypoxic CAF-induced EMT in HPAF-II cells. HPAF-II cells were treated with hypoxic 0082T CM and inhibitors (1 μM for all compounds) for 120 hr. The ability of each inhibitor to reduce vimentin expression was calculated using positive and negative controls contained on each plate (see Methods). Data are displayed as a plot of the kernel density function (displayed as density) for the percent vimentin inhibition. Inhibitors with >50% reduction in vimentin-positive cells were designated as effective (orange region of the density plot of the inhibitor screen). D) Fraction of vimentin-positive HPAF-II cells treated with CM and MET inhibitors (blue) or MEK inhibitors (orange) compared to untreated and CM-only controls. The percentage of effective inhibitors was calculated for each inhibitor class in the inhibitor library. Representative images are shown of effective (i.e., >50% vimentin reduction) MEKi- or METi-treated samples and controls. E) 0082T cells were cultured in 21% or 1% O 2 for 120 hr and assessed for HGF expression by immunofluorescence microscopy. n=3, t-test. F) Immunofluorescence microscopy was performed on HPAF-II cells treated with hypoxic 0082T CM with linsitinib (IGF1Ri, 2.5 μM), <t>PHA665752</t> (METi, 2.5 μM), both, or DMSO. G) Immunofluorescence microscopy was performed on KPCY tumor samples to determine fraction of HGF-positive CAFs (PDPN+) in oxygenated (HYP-) or hypoxic (HYP+) tumor regions. n=3, paired t-test. Data are presented as mean ± SEM for bar plots (A, B, E, F) or as a box-and- whisker plot that represent the first quartile (lower box bound), median (center bound), or third quartile (upper box bound) (G). * p <0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Pha665752 Hy 11107 Afatinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pha665752/PHA-665752/pmc11577641-41-14-22
    Average 94 stars, based on 1 article reviews
    pha665752 hy 11107 afatinib - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    90
    Beijing Solarbio Science small molecule c-met inhibitor pha665752
    A) 0082T CAF cells were cultured in 21% or 1% O 2 for 72 hr, and qRT-PCR was performed for the indicated transcripts and normalized to CASC3 . n=3, t-test. B) 0082T CAFs were cultured in 21% or 1% O 2 for 120 hr, and immunofluorescence microscopy was performed for IGF-2. n=3, t-test. C) 430 inhibitors were screened for their ability to counteract hypoxic CAF-induced EMT in HPAF-II cells. HPAF-II cells were treated with hypoxic 0082T CM and inhibitors (1 μM for all compounds) for 120 hr. The ability of each inhibitor to reduce vimentin expression was calculated using positive and negative controls contained on each plate (see Methods). Data are displayed as a plot of the kernel density function (displayed as density) for the percent vimentin inhibition. Inhibitors with >50% reduction in vimentin-positive cells were designated as effective (orange region of the density plot of the inhibitor screen). D) Fraction of vimentin-positive HPAF-II cells treated with CM and MET inhibitors (blue) or MEK inhibitors (orange) compared to untreated and CM-only controls. The percentage of effective inhibitors was calculated for each inhibitor class in the inhibitor library. Representative images are shown of effective (i.e., >50% vimentin reduction) MEKi- or METi-treated samples and controls. E) 0082T cells were cultured in 21% or 1% O 2 for 120 hr and assessed for HGF expression by immunofluorescence microscopy. n=3, t-test. F) Immunofluorescence microscopy was performed on HPAF-II cells treated with hypoxic 0082T CM with linsitinib (IGF1Ri, 2.5 μM), <t>PHA665752</t> (METi, 2.5 μM), both, or DMSO. G) Immunofluorescence microscopy was performed on KPCY tumor samples to determine fraction of HGF-positive CAFs (PDPN+) in oxygenated (HYP-) or hypoxic (HYP+) tumor regions. n=3, paired t-test. Data are presented as mean ± SEM for bar plots (A, B, E, F) or as a box-and- whisker plot that represent the first quartile (lower box bound), median (center bound), or third quartile (upper box bound) (G). * p <0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Small Molecule C Met Inhibitor Pha665752, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pha665752/small+molecule+c+met+inhibitor+pha665752/pm39217894-93-5-9
    Average 90 stars, based on 1 article reviews
    small molecule c-met inhibitor pha665752 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    Fig. 2. Stimulation of STAT3-BCL2 axis by AURKB. (A) Gene set enrichment (GSEA) data of upregulated STAT3 target genes in the H1993 PR-S2 cells. (B) Protein expressions of p-STAT3, STAT3, and GAPDH. (C) Protein expressions of p-STAT3, STAT3, p-AURKB, AURKB, and GAPDH after barasertib single or PHA665752 combination treatment of indicated drug concentration for 48 h. (D) Immunoblot analysis of the H1993 and H1993 PR-S2 cells transfected with scramble and siAURKB for 48 h. (E) and (F) The indicated protein ex pressions of the GFP and AURKB-GFP virus-infected H1993 stable cell lines and MG132 treatment for the indicated treatment time. The line graph represents the protein stability of p-STAT3. (G) and (H) RT-qPCR and immunoblotting measured the expressions of STAT3 downstream targets. (I) mRNA expression of BCL2 after treatment of 10, 100, and 1000 nM concentrations of barasertib. (J) mRNA expression levels of BCL2 and STAT3 in the scramble or siSTAT3 transfected H1993 and H1993 PR-S2 cells. (K) Protein expression of cleaved-caspase3 and BCL2 after treatment with barasertib for 48 h. The error bars represent the mean ± SEM (n = 3). Statistical analysis was performed using a two-sample t-test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001.

    Journal: Biochimica et biophysica acta. Molecular cell research

    Article Title: Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibition.

    doi: 10.1016/j.bbamcr.2025.120001

    Figure Lengend Snippet: Fig. 2. Stimulation of STAT3-BCL2 axis by AURKB. (A) Gene set enrichment (GSEA) data of upregulated STAT3 target genes in the H1993 PR-S2 cells. (B) Protein expressions of p-STAT3, STAT3, and GAPDH. (C) Protein expressions of p-STAT3, STAT3, p-AURKB, AURKB, and GAPDH after barasertib single or PHA665752 combination treatment of indicated drug concentration for 48 h. (D) Immunoblot analysis of the H1993 and H1993 PR-S2 cells transfected with scramble and siAURKB for 48 h. (E) and (F) The indicated protein ex pressions of the GFP and AURKB-GFP virus-infected H1993 stable cell lines and MG132 treatment for the indicated treatment time. The line graph represents the protein stability of p-STAT3. (G) and (H) RT-qPCR and immunoblotting measured the expressions of STAT3 downstream targets. (I) mRNA expression of BCL2 after treatment of 10, 100, and 1000 nM concentrations of barasertib. (J) mRNA expression levels of BCL2 and STAT3 in the scramble or siSTAT3 transfected H1993 and H1993 PR-S2 cells. (K) Protein expression of cleaved-caspase3 and BCL2 after treatment with barasertib for 48 h. The error bars represent the mean ± SEM (n = 3). Statistical analysis was performed using a two-sample t-test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001.

    Article Snippet: PHA665752, barasertib, VX680, MLN8237, AT9283, cycloheximide, and MG132 were purchased from Selleckchem Korea (Seoul, Korea).

    Techniques: Concentration Assay, Western Blot, Transfection, Virus, Infection, Stable Transfection, Quantitative RT-PCR, Expressing

    Fig. 3. Induced apoptotic cell death by AURKB inhibition. (A) RT-qPCR measured the mRNA expression of apoptosis-related genes in the H1993 and H1993 PR-S2 cells. (B) Western blot analysis after treatment PHA665752 or barasertib (each 1 uM) for 48 h. The bar graph represents the band intensity of BIMEL. (C) The activated form expression of BIM protein (S69 and S87) in the H1993 and H1993 PR-S2 cells. (D) Histogram indicated cell cycles of the H1993 and H1993 PR-S2 cells after AURKB inhibitor dose-dependent treatment for 24 h. The bar graph indicates the cell cycle proportion of G1, S, and G2/M. (E) Annexin-V-FITC/PI flow cytometry analysis of the H1993 and H1993 PR-S2 cells treated with 100, 250, and 500 nM of barasertib for 48 h. The bar graph represents the early and late apoptotic cell population of the barasertib-treated H1993 and H1993 PR-S2 cells. (F) Immunofluorescence analysis of nucleus (blue) and cleaved-caspase3 (green) after treatment with barasertib. Scale bars, 100 μm. The error bars represent the mean ± SEM (n = 3). Statistical analysis was performed using a two-sample t-test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001, Abbre viation: Bara, Barasertib. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Journal: Biochimica et biophysica acta. Molecular cell research

    Article Title: Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibition.

    doi: 10.1016/j.bbamcr.2025.120001

    Figure Lengend Snippet: Fig. 3. Induced apoptotic cell death by AURKB inhibition. (A) RT-qPCR measured the mRNA expression of apoptosis-related genes in the H1993 and H1993 PR-S2 cells. (B) Western blot analysis after treatment PHA665752 or barasertib (each 1 uM) for 48 h. The bar graph represents the band intensity of BIMEL. (C) The activated form expression of BIM protein (S69 and S87) in the H1993 and H1993 PR-S2 cells. (D) Histogram indicated cell cycles of the H1993 and H1993 PR-S2 cells after AURKB inhibitor dose-dependent treatment for 24 h. The bar graph indicates the cell cycle proportion of G1, S, and G2/M. (E) Annexin-V-FITC/PI flow cytometry analysis of the H1993 and H1993 PR-S2 cells treated with 100, 250, and 500 nM of barasertib for 48 h. The bar graph represents the early and late apoptotic cell population of the barasertib-treated H1993 and H1993 PR-S2 cells. (F) Immunofluorescence analysis of nucleus (blue) and cleaved-caspase3 (green) after treatment with barasertib. Scale bars, 100 μm. The error bars represent the mean ± SEM (n = 3). Statistical analysis was performed using a two-sample t-test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001, Abbre viation: Bara, Barasertib. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Article Snippet: PHA665752, barasertib, VX680, MLN8237, AT9283, cycloheximide, and MG132 were purchased from Selleckchem Korea (Seoul, Korea).

    Techniques: Inhibition, Quantitative RT-PCR, Expressing, Western Blot, Flow Cytometry, Immunofluorescence

    Fig. 4. AURKB inhibition effect in xenograft model. (A) Diagram summarizing xenograft experiment strategy in NOD-2/Shi-scid IL2rgamma(null) (N2G) mice. (B) and (C) The measurement of tumor volume (mm3) following treatment with vehicle, PHA665752 (25 mg/kg), Barasertib (50 mg/kg) and their combination for 21 days in N2G mice bearing the H1993 and H1993 PR- S2 cell xenografts. Tumor volumes were measured twice weekly by caliper (mean ± SEM, n = 6–7 for each group). (D) The fold change of the tumor volume during the period of drug injection, representing 0, 6, 14, 16, 18, and 20 days. (E) Representative hematoxylin and eosin (H&E) and Ki-67 staining images of xenograft tumors. Scale bars, 100 μm. The bar graph indicates the relative percentage of the Ki-67-positive cells. The error bars represent the mean ± SEM (n = 3). Statistical analysis was performed using a two-sample t-test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001, Abbreviation: PHA, PHA665752; Bara, Barasertib.

    Journal: Biochimica et biophysica acta. Molecular cell research

    Article Title: Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibition.

    doi: 10.1016/j.bbamcr.2025.120001

    Figure Lengend Snippet: Fig. 4. AURKB inhibition effect in xenograft model. (A) Diagram summarizing xenograft experiment strategy in NOD-2/Shi-scid IL2rgamma(null) (N2G) mice. (B) and (C) The measurement of tumor volume (mm3) following treatment with vehicle, PHA665752 (25 mg/kg), Barasertib (50 mg/kg) and their combination for 21 days in N2G mice bearing the H1993 and H1993 PR- S2 cell xenografts. Tumor volumes were measured twice weekly by caliper (mean ± SEM, n = 6–7 for each group). (D) The fold change of the tumor volume during the period of drug injection, representing 0, 6, 14, 16, 18, and 20 days. (E) Representative hematoxylin and eosin (H&E) and Ki-67 staining images of xenograft tumors. Scale bars, 100 μm. The bar graph indicates the relative percentage of the Ki-67-positive cells. The error bars represent the mean ± SEM (n = 3). Statistical analysis was performed using a two-sample t-test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001, Abbreviation: PHA, PHA665752; Bara, Barasertib.

    Article Snippet: PHA665752, barasertib, VX680, MLN8237, AT9283, cycloheximide, and MG132 were purchased from Selleckchem Korea (Seoul, Korea).

    Techniques: Inhibition, Injection, Staining

    A) 0082T CAF cells were cultured in 21% or 1% O 2 for 72 hr, and qRT-PCR was performed for the indicated transcripts and normalized to CASC3 . n=3, t-test. B) 0082T CAFs were cultured in 21% or 1% O 2 for 120 hr, and immunofluorescence microscopy was performed for IGF-2. n=3, t-test. C) 430 inhibitors were screened for their ability to counteract hypoxic CAF-induced EMT in HPAF-II cells. HPAF-II cells were treated with hypoxic 0082T CM and inhibitors (1 μM for all compounds) for 120 hr. The ability of each inhibitor to reduce vimentin expression was calculated using positive and negative controls contained on each plate (see Methods). Data are displayed as a plot of the kernel density function (displayed as density) for the percent vimentin inhibition. Inhibitors with >50% reduction in vimentin-positive cells were designated as effective (orange region of the density plot of the inhibitor screen). D) Fraction of vimentin-positive HPAF-II cells treated with CM and MET inhibitors (blue) or MEK inhibitors (orange) compared to untreated and CM-only controls. The percentage of effective inhibitors was calculated for each inhibitor class in the inhibitor library. Representative images are shown of effective (i.e., >50% vimentin reduction) MEKi- or METi-treated samples and controls. E) 0082T cells were cultured in 21% or 1% O 2 for 120 hr and assessed for HGF expression by immunofluorescence microscopy. n=3, t-test. F) Immunofluorescence microscopy was performed on HPAF-II cells treated with hypoxic 0082T CM with linsitinib (IGF1Ri, 2.5 μM), PHA665752 (METi, 2.5 μM), both, or DMSO. G) Immunofluorescence microscopy was performed on KPCY tumor samples to determine fraction of HGF-positive CAFs (PDPN+) in oxygenated (HYP-) or hypoxic (HYP+) tumor regions. n=3, paired t-test. Data are presented as mean ± SEM for bar plots (A, B, E, F) or as a box-and- whisker plot that represent the first quartile (lower box bound), median (center bound), or third quartile (upper box bound) (G). * p <0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Journal: bioRxiv

    Article Title: Hypoxia-induced histone methylation and NF-κB activation in pancreas cancer fibroblasts promote EMT-supportive growth factor secretion

    doi: 10.1101/2025.01.30.635486

    Figure Lengend Snippet: A) 0082T CAF cells were cultured in 21% or 1% O 2 for 72 hr, and qRT-PCR was performed for the indicated transcripts and normalized to CASC3 . n=3, t-test. B) 0082T CAFs were cultured in 21% or 1% O 2 for 120 hr, and immunofluorescence microscopy was performed for IGF-2. n=3, t-test. C) 430 inhibitors were screened for their ability to counteract hypoxic CAF-induced EMT in HPAF-II cells. HPAF-II cells were treated with hypoxic 0082T CM and inhibitors (1 μM for all compounds) for 120 hr. The ability of each inhibitor to reduce vimentin expression was calculated using positive and negative controls contained on each plate (see Methods). Data are displayed as a plot of the kernel density function (displayed as density) for the percent vimentin inhibition. Inhibitors with >50% reduction in vimentin-positive cells were designated as effective (orange region of the density plot of the inhibitor screen). D) Fraction of vimentin-positive HPAF-II cells treated with CM and MET inhibitors (blue) or MEK inhibitors (orange) compared to untreated and CM-only controls. The percentage of effective inhibitors was calculated for each inhibitor class in the inhibitor library. Representative images are shown of effective (i.e., >50% vimentin reduction) MEKi- or METi-treated samples and controls. E) 0082T cells were cultured in 21% or 1% O 2 for 120 hr and assessed for HGF expression by immunofluorescence microscopy. n=3, t-test. F) Immunofluorescence microscopy was performed on HPAF-II cells treated with hypoxic 0082T CM with linsitinib (IGF1Ri, 2.5 μM), PHA665752 (METi, 2.5 μM), both, or DMSO. G) Immunofluorescence microscopy was performed on KPCY tumor samples to determine fraction of HGF-positive CAFs (PDPN+) in oxygenated (HYP-) or hypoxic (HYP+) tumor regions. n=3, paired t-test. Data are presented as mean ± SEM for bar plots (A, B, E, F) or as a box-and- whisker plot that represent the first quartile (lower box bound), median (center bound), or third quartile (upper box bound) (G). * p <0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Article Snippet: PHA665752 (Santa Cruz Biotechnology) and linsitinib (Selleck) were used at 2.5 μM ( , ).

    Techniques: Cell Culture, Quantitative RT-PCR, Immunofluorescence, Microscopy, Expressing, Inhibition, Whisker Assay

    A) 0082T CAFs were cultured in 21% or 1% O 2 for 120 hr, and qRT-PCR was performed on extracted mRNA for HGF transcripts. CASC3 was used for normalization. n=3. B) Conditioned medium was collected from 0082T cells cultured in 21% or 1% O 2 and analyzed for HGF by ELISA. n=3, t-test. C) HPAF-II cells were untreated or treated with conditioned medium (CM) from PSCs grown at 1% O 2 +/- PHA665752 (METi, 2.5 μM) for 120 hr. Immunofluorescence microscopy was performed for the indicated proteins. n=3, one-way ANOVA with Tukey’s multiple comparison test. D) HPAF-II cells were treated with IGF-2 (100 ng/mL), HGF (5 ng/mL), or IGF-2+HGF for 120 hr. Immunofluorescence microscopy was performed for the indicated proteins. n=3, one-way ANOVA with Tukey’s multiple comparison test. E) Fluorescence-based immunohistochemistry was performed on sections of KPCY tumors for podoplanin (PDPN) and Hypoxyprobe (HYP) to calculate the percentage of CAFs within hypoxic regions. n=3. F) In sections of subcutaneous tumors formed using KPCY-derived 7160.c2 cells, HGF expression was assessed in Hypoxyprobe-positive and -negative CAFs (PDPN+ cells). n=3, t-test. Data are presented as mean ± SEM for bar plots (A, B, C, D, F) or as a mosaic plot indicating the percentage of PDPN+ cells that are positive or negative for Hypoxyprobe (HYP) across biological replicates. * p <0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Journal: bioRxiv

    Article Title: Hypoxia-induced histone methylation and NF-κB activation in pancreas cancer fibroblasts promote EMT-supportive growth factor secretion

    doi: 10.1101/2025.01.30.635486

    Figure Lengend Snippet: A) 0082T CAFs were cultured in 21% or 1% O 2 for 120 hr, and qRT-PCR was performed on extracted mRNA for HGF transcripts. CASC3 was used for normalization. n=3. B) Conditioned medium was collected from 0082T cells cultured in 21% or 1% O 2 and analyzed for HGF by ELISA. n=3, t-test. C) HPAF-II cells were untreated or treated with conditioned medium (CM) from PSCs grown at 1% O 2 +/- PHA665752 (METi, 2.5 μM) for 120 hr. Immunofluorescence microscopy was performed for the indicated proteins. n=3, one-way ANOVA with Tukey’s multiple comparison test. D) HPAF-II cells were treated with IGF-2 (100 ng/mL), HGF (5 ng/mL), or IGF-2+HGF for 120 hr. Immunofluorescence microscopy was performed for the indicated proteins. n=3, one-way ANOVA with Tukey’s multiple comparison test. E) Fluorescence-based immunohistochemistry was performed on sections of KPCY tumors for podoplanin (PDPN) and Hypoxyprobe (HYP) to calculate the percentage of CAFs within hypoxic regions. n=3. F) In sections of subcutaneous tumors formed using KPCY-derived 7160.c2 cells, HGF expression was assessed in Hypoxyprobe-positive and -negative CAFs (PDPN+ cells). n=3, t-test. Data are presented as mean ± SEM for bar plots (A, B, C, D, F) or as a mosaic plot indicating the percentage of PDPN+ cells that are positive or negative for Hypoxyprobe (HYP) across biological replicates. * p <0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Article Snippet: PHA665752 (Santa Cruz Biotechnology) and linsitinib (Selleck) were used at 2.5 μM ( , ).

    Techniques: Cell Culture, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Microscopy, Comparison, Fluorescence, Immunohistochemistry, Derivative Assay, Expressing